TCP is owned and operated by The Hospital for Sick Children and Mount Sinai Hospital. It is a unique resource that provides critical tools (mouse and rat models) and services for high calibre biomedical research. TCP was designated a national research facility by the Canada Foundation for Innovation in 2014, and a Genomics Technology Platform by Genome Canada in 2015.
TCP’s facility is uniquely programmed to design, produce, manage, analyse, and dis- tribute mouse models to enable discovery, translational studies, preclinical bioavailability, safety, and effect evaluation for therapeutic discovery.
In six Core Units, the facility provides these services:
- Model Production: mouse and rat production, genetic quality control, and colony management.
- Clinical Phenotyping: comprehensive analysis of gene function, drug target validation, and evaluation of treatment effect in mice.
- Pathology: necropsy, gross pathology, histology, immunohistochemistry, semi- and quantitative image analysis, and histopathology.
- Imaging: multi-modality imaging and collaborative technology development.
- Infection and Inflammation: assessment of genes associated with resistance or susceptibility to infectious disease and the immune response.
- Cryopreservation and Recovery: embryo, ES cell, and sperm ser- vices, in addition to the global acquisition and distribution of rodent models. TCP is supported by its multidisciplinary informatics team and a senior biostatistician.